Rigel Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

• Rigel Pharmaceuticals Inc RIGL.OQ reported quarterly adjusted earnings of 70 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -30 cents. The mean expectation of six analysts for the quarter was for earnings of 6 cents per share. Wall Street expected results to range from -21 cents to 32 cents per share.

• Revenue rose 96.6% to $55.31 million from a year ago; analysts expected $41.93 million.

• Rigel Pharmaceuticals Inc's reported EPS for the quarter was 70 cents​.

• The company reported quarterly net income of $12.42 million.

• Rigel Pharmaceuticals Inc shares had fallen by 6.8% this quarter and gained 4.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is "hold."

Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $16.00

This summary was machine generated from LSEG data November 8 at 05:12 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)